TP53 and cancer: Sensitivity to PRMT5 inhibition has also been suggested in MYC-driven, TP53 wild-type (WT), and spliceosomal mutant cancers, emphasizing its role in oncogenic splicing (Koh et al, 2015; Li & Diehl, 2015; Lee et al, 2016).